EVOK Key Statistics, Chart & Performance
The current stock price of EVOK is 10.93 USD. In the past month the price increased by 2.53%. In the past year, price increased by 164.01%.
EVOK Latest News, Press Relases and Analysis
EVOK Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 47 | 977.11B | ||
| JNJ | JOHNSON & JOHNSON | 19.78 | 494.70B | ||
| MRK | MERCK & CO. INC. | 11.61 | 253.84B | ||
| PFE | PFIZER INC | 7.99 | 145.38B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.77 | 103.74B | ||
| ZTS | ZOETIS INC | 19.33 | 54.02B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.64 | 22.86B | ||
| VTRS | VIATRIS INC | 4.65 | 12.49B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.1 | 11.02B | ||
| CORT | CORCEPT THERAPEUTICS INC | 95.08 | 8.80B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.45B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.30B |
Related stock screener links
About EVOK
Company Profile
Evoke Pharma, Inc. is a pharmaceutical company, which engages in the development of drugs for the treatment of gastrointestinal disorders and diseases. The company is headquartered in Solana Beach, California and currently employs 3 full-time employees. The company went IPO on 2013-09-25. The company develops, commercializes and markets GIMOTI, a nasal spray formulation of metoclopramide, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults. Gimoti is a dopamine antagonist / mixed 5-HT3 antagonist / 5-HT4 agonist with pro-motility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis. Gimoti offers systemic delivery by nasal spray administration. The company has developed a nasal formulation of metoclopramide to provide its targeted patient population with recurrent symptoms of diabetic gastroparesis with a product that is systemically delivered as an alternative to the oral or intravenous routes of administration. The nasal formulation delivers metoclopramide to patients with delayed gastric emptying and/or frequent vomiting.
Company Info
EVOKE PHARMA INC
420 Stevens Avenue, Suite 230
Solana Beach CALIFORNIA 92075 US
CEO: David A. Gonyer
Employees: 3
Phone: 18583451494
EVOKE PHARMA INC / EVOK FAQ
Can you describe the business of EVOKE PHARMA INC?
Evoke Pharma, Inc. is a pharmaceutical company, which engages in the development of drugs for the treatment of gastrointestinal disorders and diseases. The company is headquartered in Solana Beach, California and currently employs 3 full-time employees. The company went IPO on 2013-09-25. The company develops, commercializes and markets GIMOTI, a nasal spray formulation of metoclopramide, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults. Gimoti is a dopamine antagonist / mixed 5-HT3 antagonist / 5-HT4 agonist with pro-motility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis. Gimoti offers systemic delivery by nasal spray administration. The company has developed a nasal formulation of metoclopramide to provide its targeted patient population with recurrent symptoms of diabetic gastroparesis with a product that is systemically delivered as an alternative to the oral or intravenous routes of administration. The nasal formulation delivers metoclopramide to patients with delayed gastric emptying and/or frequent vomiting.
What is the stock price of EVOKE PHARMA INC today?
The current stock price of EVOK is 10.93 USD. The price increased by 0.18% in the last trading session.
What is the dividend status of EVOKE PHARMA INC?
EVOK does not pay a dividend.
What is the ChartMill technical and fundamental rating of EVOK stock?
EVOK has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the market capitalization of EVOK stock?
EVOKE PHARMA INC (EVOK) has a market capitalization of 18.80M USD. This makes EVOK a Nano Cap stock.
What is the Short Interest ratio of EVOKE PHARMA INC (EVOK) stock?
The outstanding short interest for EVOKE PHARMA INC (EVOK) is 1.15% of its float.
EVOK Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to EVOK. When comparing the yearly performance of all stocks, EVOK is one of the better performing stocks in the market, outperforming 98.2% of all stocks.
EVOK Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to EVOK. EVOK may be in some trouble as it scores bad on both profitability and health.
EVOK Financial Highlights
Over the last trailing twelve months EVOK reported a non-GAAP Earnings per Share(EPS) of -2.21. The EPS increased by 79.89% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -33.51% | ||
| ROE | -123.04% | ||
| Debt/Equity | 1.14 |
EVOK Forecast & Estimates
7 analysts have analysed EVOK and the average price target is 18.36 USD. This implies a price increase of 67.98% is expected in the next year compared to the current price of 10.93.
For the next year, analysts expect an EPS growth of 55.96% and a revenue growth 57.78% for EVOK